Table 2 Lenalidomide and incidence of second primary malignancies
From: Thalidomide and its analogues in the treatment of Multiple Myeloma
Study | Patient population | Treatment | Numbers | SPM |
|---|---|---|---|---|
MM-015 | Elderly transplant ineligible patients | MP | 153 | (3%) |
MPR | 152 | (7%) | ||
MPR-R | 150 | (7%) | ||
IFM 2005-02 | Newly diagnosed post stem cell transplant | Placebo | 302 | 11 (4%) |
Lenolidomide | 306 | 26 (8%) | ||
CALGB 100104 | Newly diagnosed post stem cell transplant | Placebo | 229 | 6 (2.6%) |
Lenolidomide | 231 | 18 (7.8%) |